78 results on '"Conroy T"'
Search Results
2. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial
3. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
4. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France
5. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
6. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer
7. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
8. Reply to the Letter to the Editor ‘Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten’ (in regard to “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”) by Huguet et al.
9. Is neoadjuvant folfox an effective treatment only in a very selected favorable subgroup of locally advanced rectal cancer?
10. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?
11. Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: The FATSEIN study
12. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial
13. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
14. LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
15. 1215P Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
16. Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer
17. Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation
18. Nurses’ performance and attitudes in nutritional care delivery for hospitalized patients with disease related malnutrition; an analysis of qualitative data.
19. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
20. Satisfaction par rapport aux soins en oncologie évaluée par le QLQ-SAT32 de l’EORTC : comparaison entre auto-passation et entretien téléphonique: Cancer in patient satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response
21. 1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial
22. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer
23. Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer
24. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
25. Quality of life in patients with advanced colorectal cancer: what has been learnt?
26. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients
27. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
28. Mesure de la qualité de vie des patients atteints de cancer colorectal métastatique : techniques et principaux résultats
29. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
30. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer
31. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study
32. Moving toward precision oncology centers V2.0
33. Traitements non chirurgicaux des cancers de l'œsophage
34. Recommandations pour la pratique clinique et évolution de la survie des patients atteints d’un cancer rectal, étude de la population de 1984 à 2003 dans le département du Doubs
35. LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
36. 422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs)
37. Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283–288
38. Analyse conjointe de la survie et de la qualité de vie relative à la santé chez des patients atteints de cancer du pancréas métastatique. Application aux données de l’essai clinique PRODIGE 4/ACCORD 11
39. Rôle causal de la fatigue sur la détérioration de la qualité de vie pendant la chimiothérapie pour cancer du sein : application des modèles structuraux marginaux
40. Modélisation conjointe de la trajectoire de qualité de vie relative à la santé et du temps de « dropout » pour la prise en compte des données manquantes monotones potentiellement informatives : application aux données de l’essai clinique ACCORD 17
41. 193O - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45
42. Impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer
43. Prise en compte des données manquantes potentiellement informatives dans l’analyse longitudinale de la qualité de vie relative à la santé sur les données de l’essai clinique PRODIGE5/ACCORD 17
44. La pratique régulière d’une activité physique : un déterminant important de la fatigue et de la qualité de vie pendant le traitement adjuvant du cancer du sein
45. 477O - Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
46. 746P - COnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT)
47. Développement et validation préliminaire du questionnaire EORTC mesurant la satisfaction des soins des patients en cancérologie
48. Évaluation de trois méthodes longitudinales pour l’analyse de la qualité de vie relative à la santé en oncologie
49. Impact de l’occurrence de l’effet response shift sur la détermination de la différence minimale cliniquement importante d’un score de qualité de vie
50. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.